{"title":"第三代和第四代QuantiFERON-TB金测定在印度妊娠阶段的不一致。","authors":"Vandana Kulkarni , Mallika Alexander , Ramesh Bhosale , Divyashri Jain , Prasad Deshpande , Emily Shira Gitlin , Arthi Vaidyanathan , Andrea Chalem , Shilpa Naik , Nikhil Gupte , Neelu Nawani , Amita Gupta , Jyoti Mathad","doi":"10.1016/j.jctube.2024.100504","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Pregnancy and HIV affect CD4+ T lymphocytes and impact performance of QuantiFERON-TB Gold (QFT). We compared the results of QFT with QuantiFERON-TB Gold Plus (QFT-Plus), which also measures CD8+ responses to TB antigens, during pregnancy and postpartum.</div></div><div><h3>Methods</h3><div>We screened 516 pregnant women for TB infection (TBI) with IGRA. From 165 IGRA + pregnant women, QFT vs QFT-Plus results were compared at delivery and postpartum. Longitudinal changes in QFT-Plus were assessed in 74 pregnant women who received QFT-Plus testing at pregnancy, delivery, and postpartum.</div></div><div><h3>Results</h3><div>Through cross-sectional analysis of the IGRA + cohort, QFT-Plus showed higher positivity than QFT (80 % vs 65 %, p = 0.04) at delivery but no difference postpartum. Among 35 women with HIV, QFT-Plus returned more positive results than QFT at delivery and postpartum (76 % vs 47 %, p = 0.08; 90 % vs 80 %, p = 0.54), though not statistically significant. Longitudinally, QFT-Plus positivity by TB1 or TB2 was highest antepartum vs. delivery and postpartum (74 % vs. 58 % vs. 62 %; p = 0.09) and performed better than TB1 alone (100 % vs 90 %, p = 0.04) in women without HIV but not in women with HIV.</div></div><div><h3>Conclusions</h3><div>Performance of QFT-Plus was consistent across pregnancy, including at delivery when QFT positivity is lower. QFT-Plus may enhance antenatal TBI detection among pregnant women.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"38 ","pages":"Article 100504"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697401/pdf/","citationCount":"0","resultStr":"{\"title\":\"Discordance of 3rd and 4th generation QuantiFERON-TB Gold assays by pregnancy stages in India\",\"authors\":\"Vandana Kulkarni , Mallika Alexander , Ramesh Bhosale , Divyashri Jain , Prasad Deshpande , Emily Shira Gitlin , Arthi Vaidyanathan , Andrea Chalem , Shilpa Naik , Nikhil Gupte , Neelu Nawani , Amita Gupta , Jyoti Mathad\",\"doi\":\"10.1016/j.jctube.2024.100504\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Pregnancy and HIV affect CD4+ T lymphocytes and impact performance of QuantiFERON-TB Gold (QFT). We compared the results of QFT with QuantiFERON-TB Gold Plus (QFT-Plus), which also measures CD8+ responses to TB antigens, during pregnancy and postpartum.</div></div><div><h3>Methods</h3><div>We screened 516 pregnant women for TB infection (TBI) with IGRA. From 165 IGRA + pregnant women, QFT vs QFT-Plus results were compared at delivery and postpartum. Longitudinal changes in QFT-Plus were assessed in 74 pregnant women who received QFT-Plus testing at pregnancy, delivery, and postpartum.</div></div><div><h3>Results</h3><div>Through cross-sectional analysis of the IGRA + cohort, QFT-Plus showed higher positivity than QFT (80 % vs 65 %, p = 0.04) at delivery but no difference postpartum. Among 35 women with HIV, QFT-Plus returned more positive results than QFT at delivery and postpartum (76 % vs 47 %, p = 0.08; 90 % vs 80 %, p = 0.54), though not statistically significant. Longitudinally, QFT-Plus positivity by TB1 or TB2 was highest antepartum vs. delivery and postpartum (74 % vs. 58 % vs. 62 %; p = 0.09) and performed better than TB1 alone (100 % vs 90 %, p = 0.04) in women without HIV but not in women with HIV.</div></div><div><h3>Conclusions</h3><div>Performance of QFT-Plus was consistent across pregnancy, including at delivery when QFT positivity is lower. QFT-Plus may enhance antenatal TBI detection among pregnant women.</div></div>\",\"PeriodicalId\":37942,\"journal\":{\"name\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"volume\":\"38 \",\"pages\":\"Article 100504\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697401/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405579424000913\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579424000913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景：妊娠和HIV影响CD4+ T淋巴细胞，影响QuantiFERON-TB Gold （QFT）的性能。我们将QFT的结果与QuantiFERON-TB Gold Plus （QFT-Plus）的结果进行了比较，QFT-Plus也测量了CD8+在怀孕和产后对TB抗原的反应。方法：采用IGRA对516例孕妇进行TB感染筛查。在165名IGRA阳性孕妇中，比较了QFT和QFT- plus在分娩和产后的结果。对74名在怀孕、分娩和产后接受QFT-Plus检测的孕妇进行QFT-Plus的纵向变化评估。结果：通过IGRA +队列的横断面分析，分娩时QFT- plus的阳性率高于QFT (80% vs 65%, p = 0.04)，但产后无差异。在35名感染艾滋病毒的妇女中，QFT- plus在分娩和产后的阳性结果比QFT更多(76%比47%，p = 0.08；90% vs 80%, p = 0.54)，但没有统计学意义。纵向上，TB1或TB2的QFT-Plus阳性在产前、分娩和产后最高(74%、58%、62%；p = 0.09)，并且在未感染艾滋病毒的妇女中优于单独使用TB1 (100% vs 90%, p = 0.04)，而在感染艾滋病毒的妇女中则不然。结论：QFT- plus的表现在整个怀孕期间是一致的，包括在分娩时，QFT阳性较低。QFT-Plus可能提高孕妇产前TBI的检测。
Discordance of 3rd and 4th generation QuantiFERON-TB Gold assays by pregnancy stages in India
Background
Pregnancy and HIV affect CD4+ T lymphocytes and impact performance of QuantiFERON-TB Gold (QFT). We compared the results of QFT with QuantiFERON-TB Gold Plus (QFT-Plus), which also measures CD8+ responses to TB antigens, during pregnancy and postpartum.
Methods
We screened 516 pregnant women for TB infection (TBI) with IGRA. From 165 IGRA + pregnant women, QFT vs QFT-Plus results were compared at delivery and postpartum. Longitudinal changes in QFT-Plus were assessed in 74 pregnant women who received QFT-Plus testing at pregnancy, delivery, and postpartum.
Results
Through cross-sectional analysis of the IGRA + cohort, QFT-Plus showed higher positivity than QFT (80 % vs 65 %, p = 0.04) at delivery but no difference postpartum. Among 35 women with HIV, QFT-Plus returned more positive results than QFT at delivery and postpartum (76 % vs 47 %, p = 0.08; 90 % vs 80 %, p = 0.54), though not statistically significant. Longitudinally, QFT-Plus positivity by TB1 or TB2 was highest antepartum vs. delivery and postpartum (74 % vs. 58 % vs. 62 %; p = 0.09) and performed better than TB1 alone (100 % vs 90 %, p = 0.04) in women without HIV but not in women with HIV.
Conclusions
Performance of QFT-Plus was consistent across pregnancy, including at delivery when QFT positivity is lower. QFT-Plus may enhance antenatal TBI detection among pregnant women.
期刊介绍：
Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
